[
  {
    "title": "沃森生物董事长李云春拟增持1亿元至1.5亿元公司股票：增持不设定价格区间",
    "href": "http://stock.jrj.com.cn/2022/12/21113237227775.shtml",
    "datetime": "2022-12-21 11:32:51",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：董事长及其控制的企业拟以1亿-1.5亿元增持公司股份",
    "href": "http://stock.jrj.com.cn/2022/12/20200637226536.shtml",
    "datetime": "2022-12-20 20:06:39",
    "code": "300142"
  },
  {
    "title": "沃森生物：董事长及其控制的企业拟增持1亿元-1.5亿元股份",
    "href": "http://stock.jrj.com.cn/2022/12/20194237226441.shtml",
    "datetime": "2022-12-20 19:42:08",
    "code": "300142"
  },
  {
    "title": "晚间公告全知道：沃森生物的新冠变异株mRNA疫苗获得Ⅲ期临床试验伦理审查批件",
    "href": "http://stock.jrj.com.cn/2022/12/16211637219497.shtml",
    "datetime": "2022-12-16 21:16:34",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：新冠病毒变异株mRNA疫苗(S蛋白嵌合体)获得Ⅲ期临床试验伦理审查批件",
    "href": "http://stock.jrj.com.cn/2022/12/16184537219044.shtml",
    "datetime": "2022-12-16 18:45:56",
    "code": "300142"
  },
  {
    "title": "沃森生物：新冠变异株mRNA疫苗获得Ⅲ期临床试验伦理审查批件",
    "href": "http://stock.jrj.com.cn/2022/12/16183637218949.shtml",
    "datetime": "2022-12-16 18:36:19",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司新冠变异株mRNA疫苗的Ⅲa期和Ⅲb期预计将于近期完成入组",
    "href": "http://stock.jrj.com.cn/2022/12/11153637203835.shtml",
    "datetime": "2022-12-11 15:36:21",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)及子公司收到两项发明专利证书",
    "href": "http://stock.jrj.com.cn/2022/12/07184837195867.shtml",
    "datetime": "2022-12-07 18:48:09",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪泽润拟向昆明红十字会捐赠150剂双价HPV疫苗用于特定人群接种",
    "href": "http://stock.jrj.com.cn/2022/12/07184637195870.shtml",
    "datetime": "2022-12-07 18:46:04",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟向“爱婴行动——爱婴医院出院健康指导”项目捐赠545万元",
    "href": "http://stock.jrj.com.cn/2022/12/07184537195874.shtml",
    "datetime": "2022-12-07 18:45:00",
    "code": "300142"
  },
  {
    "title": "A股异动丨沃森生物涨逾4% mRNA新冠疫苗获临床试验伦理快速审查批件",
    "href": "http://stock.jrj.com.cn/2022/11/16093437142525.shtml",
    "datetime": "2022-11-16 09:34:41",
    "code": "300142"
  },
  {
    "title": "沃森生物：新冠疫苗获得临床试验快速审查批件",
    "href": "http://stock.jrj.com.cn/2022/11/15184437141110.shtml",
    "datetime": "2022-11-15 18:44:35",
    "code": "300142"
  },
  {
    "title": "沃森生物：新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）获得临床试验伦理快速审查批件",
    "href": "http://stock.jrj.com.cn/2022/11/15180637141000.shtml",
    "datetime": "2022-11-15 18:06:37",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：新型冠状病毒变异株mRNA疫苗(S蛋白嵌合体)获得临床试验伦理快速审查批件",
    "href": "http://stock.jrj.com.cn/2022/11/15180037141018.shtml",
    "datetime": "2022-11-15 18:00:12",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：新冠病毒变异株mRNA疫苗(S蛋白嵌合体)获得临床试验伦理审查批件",
    "href": "http://stock.jrj.com.cn/2022/11/03193037110785.shtml",
    "datetime": "2022-11-03 19:30:21",
    "code": "300142"
  },
  {
    "title": "沃森生物2022年前三季度净利5.31亿同比增长45.84% HPV疫苗销售量增加",
    "href": "http://stock.jrj.com.cn/2022/10/25051137080105.shtml",
    "datetime": "2022-10-25 05:11:49",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：第三季度净利增144.35%至1.10亿元",
    "href": "http://stock.jrj.com.cn/2022/10/24201337079308.shtml",
    "datetime": "2022-10-24 20:13:40",
    "code": "300142"
  },
  {
    "title": "沃森生物董事会换届：股东大会上无董事全票通过 部分董事得票率仅为63%",
    "href": "http://stock.jrj.com.cn/2022/10/14163237056220.shtml",
    "datetime": "2022-10-14 16:32:12",
    "code": "300142"
  },
  {
    "title": "晚间公告全知道：沃森生物研发生产的新冠病毒mRNA疫苗获印尼紧急使用授权、赛为智能实控人周勇被调查并留置",
    "href": "http://stock.jrj.com.cn/2022/09/30211037035350.shtml",
    "datetime": "2022-09-30 21:10:21",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：新冠病毒mRNA疫苗获印尼紧急使用授权(EUA)",
    "href": "http://stock.jrj.com.cn/2022/09/30174237034556.shtml",
    "datetime": "2022-09-30 17:42:35",
    "code": "300142"
  },
  {
    "title": "沃森生物：新冠病毒mRNA疫苗获印尼紧急使用授权",
    "href": "http://stock.jrj.com.cn/2022/09/30174237034464.shtml",
    "datetime": "2022-09-30 17:42:00",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：解聘张荔董事会秘书职务、其被留置调查系个人原因",
    "href": "http://stock.jrj.com.cn/2022/09/27215137026258.shtml",
    "datetime": "2022-09-27 21:51:15",
    "code": "300142"
  },
  {
    "title": "沃森生物：解聘董秘张荔 其因个人原因被留置调查",
    "href": "http://stock.jrj.com.cn/2022/09/27205937026110.shtml",
    "datetime": "2022-09-27 20:59:41",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：回购方案已实施完毕、累计回购599.9943万股",
    "href": "http://stock.jrj.com.cn/2022/09/16205637001693.shtml",
    "datetime": "2022-09-16 20:56:03",
    "code": "300142"
  },
  {
    "title": "利好来了？670亿疫苗龙头官宣，九价HPV启动Ⅲ期临床试验！董秘刚被留置调查",
    "href": "http://stock.jrj.com.cn/2022/09/08083136982028.shtml",
    "datetime": "2022-09-08 08:31:00",
    "code": "300142"
  },
  {
    "title": "晚间公告全知道：沃森生物称九价HPV疫苗启动Ⅲ期临床试验、天顺股份市盈率显著高于行业市盈率水平",
    "href": "http://stock.jrj.com.cn/2022/09/07213136981498.shtml",
    "datetime": "2022-09-07 21:31:50",
    "code": "300142"
  },
  {
    "title": "沃森生物：九价HPV疫苗启动Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/07191736981115.shtml",
    "datetime": "2022-09-07 19:17:31",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：九价HPV疫苗启动III期临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/07185036981073.shtml",
    "datetime": "2022-09-07 18:50:31",
    "code": "300142"
  },
  {
    "title": "沃森生物董秘被查年薪299万 上半年扣非倍增股价跌逾50%",
    "href": "http://stock.jrj.com.cn/2022/09/07103836979256.shtml",
    "datetime": "2022-09-07 10:38:55",
    "code": "300142"
  },
  {
    "title": "董秘张荔被留置调查 沃森生物股价跌1.65%",
    "href": "http://stock.jrj.com.cn/2022/09/06093036975734.shtml",
    "datetime": "2022-09-06 09:30:05",
    "code": "300142"
  },
  {
    "title": "云南疫苗龙头“美女董秘”出事了？持股市值超4500万元，年薪比董事长高；公司：各项经营管理工作均正常",
    "href": "http://stock.jrj.com.cn/2022/09/06081736975573.shtml",
    "datetime": "2022-09-06 08:17:55",
    "code": "300142"
  },
  {
    "title": "“留置调查”！700亿疫苗巨头董秘出事",
    "href": "http://stock.jrj.com.cn/2022/09/06064136975387.shtml",
    "datetime": "2022-09-06 06:41:25",
    "code": "300142"
  },
  {
    "title": "沃森生物：董事会秘书张荔因个人原因被留置调查",
    "href": "http://stock.jrj.com.cn/2022/09/05204136975018.shtml",
    "datetime": "2022-09-05 20:41:14",
    "code": "300142"
  },
  {
    "title": "沃森生物：重组新型冠状病毒变异株疫苗（CHO细胞）获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/09/01192236963956.shtml",
    "datetime": "2022-09-01 19:22:33",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：新型冠状病毒变异株mRNA疫苗(S蛋白嵌合体)获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/09/01192136963973.shtml",
    "datetime": "2022-09-01 19:21:29",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：重组新型冠状病毒变异株疫苗(CHO细胞)获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/09/01192136963974.shtml",
    "datetime": "2022-09-01 19:21:05",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)截至8月底已累计回购317.68万股",
    "href": "http://stock.jrj.com.cn/2022/09/01191936963944.shtml",
    "datetime": "2022-09-01 19:19:25",
    "code": "300142"
  },
  {
    "title": "沃森生物：2022年上半年净利润4.21亿元，同比增31.9%",
    "href": "http://stock.jrj.com.cn/2022/08/11101636889699.shtml",
    "datetime": "2022-08-11 10:16:50",
    "code": "300142"
  },
  {
    "title": "沃森生物2022年上半年净利4.21亿同比增长31.9% 新增双价HPV疫苗销售量增加",
    "href": "http://stock.jrj.com.cn/2022/08/10215336888360.shtml",
    "datetime": "2022-08-10 21:53:07",
    "code": "300142"
  },
  {
    "title": "沃森生物：上半年归母净利润4.21亿元，同比增31.9%",
    "href": "http://stock.jrj.com.cn/2022/08/10204436888172.shtml",
    "datetime": "2022-08-10 20:44:31",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟申请综合授信及流动资金贷款合计12.3亿元",
    "href": "http://stock.jrj.com.cn/2022/08/10192636887848.shtml",
    "datetime": "2022-08-10 19:26:36",
    "code": "300142"
  },
  {
    "title": "沃森生物：拟发行不超12.35亿元可转债",
    "href": "http://stock.jrj.com.cn/2022/08/10181736887484.shtml",
    "datetime": "2022-08-10 18:17:10",
    "code": "300142"
  },
  {
    "title": "沃森生物：上半年净利润4.21亿元 同比增31.9%",
    "href": "http://stock.jrj.com.cn/2022/08/10180136887433.shtml",
    "datetime": "2022-08-10 18:01:53",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟发行可转债募资不超12.35亿元、用于玉溪沃森多糖结合疫苗扩产扩能项目等等",
    "href": "http://stock.jrj.com.cn/2022/08/10175936887416.shtml",
    "datetime": "2022-08-10 17:59:29",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟用1.16亿元募资实施玉溪沃森两化融合建设项目",
    "href": "http://stock.jrj.com.cn/2022/08/10175936887419.shtml",
    "datetime": "2022-08-10 17:59:12",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)半年度扣非净利润4.81亿元、同比增长100.47%",
    "href": "http://stock.jrj.com.cn/2022/08/10175536887424.shtml",
    "datetime": "2022-08-10 17:55:10",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：可行权的股票期权为739万份、行权价为28.403元/股",
    "href": "http://stock.jrj.com.cn/2022/08/08164636879247.shtml",
    "datetime": "2022-08-08 16:46:19",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：截至7月底已累计回购200万股",
    "href": "http://stock.jrj.com.cn/2022/08/01174836859833.shtml",
    "datetime": "2022-08-01 17:48:22",
    "code": "300142"
  },
  {
    "title": "沃森生物：子公司拟对外捐赠23价肺炎球菌多糖疫苗",
    "href": "http://stock.jrj.com.cn/2022/07/26190936844533.shtml",
    "datetime": "2022-07-26 19:09:53",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟新增捐赠不超15万剂23价肺炎疫苗",
    "href": "http://stock.jrj.com.cn/2022/07/26182636844386.shtml",
    "datetime": "2022-07-26 18:26:33",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：上海泽润近日获得2项发明专利证书",
    "href": "http://stock.jrj.com.cn/2022/07/15163636816088.shtml",
    "datetime": "2022-07-15 16:36:16",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)截至6月底已累计回购40.71万股",
    "href": "http://stock.jrj.com.cn/2022/07/01192636776267.shtml",
    "datetime": "2022-07-01 19:26:39",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：6月28日首次回购17万股",
    "href": "http://stock.jrj.com.cn/2022/06/28174636765028.shtml",
    "datetime": "2022-06-28 17:46:18",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司终止重组EV71疫苗研发",
    "href": "http://stock.jrj.com.cn/2022/06/13172436724600.shtml",
    "datetime": "2022-06-13 17:24:59",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：尚未实施股份回购",
    "href": "http://stock.jrj.com.cn/2022/06/02172736700892.shtml",
    "datetime": "2022-06-02 17:27:47",
    "code": "300142"
  },
  {
    "title": "沃森生物：双价HPV疫苗首批产品获得批签发证明",
    "href": "http://stock.jrj.com.cn/2022/05/24155736674139.shtml",
    "datetime": "2022-05-24 15:57:38",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司双价HPV疫苗产品获得首批批签发证明",
    "href": "http://stock.jrj.com.cn/2022/05/24154336674107.shtml",
    "datetime": "2022-05-24 15:43:57",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森近日收到13价肺炎结合疫苗首笔100万剂采购订单",
    "href": "http://stock.jrj.com.cn/2022/05/12174836643424.shtml",
    "datetime": "2022-05-12 17:48:36",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：尚未买入公司股票",
    "href": "http://stock.jrj.com.cn/2022/05/05165836570215.shtml",
    "datetime": "2022-05-05 16:58:25",
    "code": "300142"
  },
  {
    "title": "沃森生物：2022年一季度实现营收6.56亿元，同比增长51.27%",
    "href": "http://stock.jrj.com.cn/2022/04/28183736494189.shtml",
    "datetime": "2022-04-28 18:37:35",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)年报推10派0.27元 股权登记日4月25日",
    "href": "http://stock.jrj.com.cn/2022/04/19200836401963.shtml",
    "datetime": "2022-04-19 20:08:07",
    "code": "300142"
  },
  {
    "title": "突降“黑天鹅”沃森生物股价跳水 二价HPV疫苗后市如何将成谜",
    "href": "http://stock.jrj.com.cn/2022/04/15074336340851.shtml",
    "datetime": "2022-04-15 07:43:10",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：尚未买入公司股票",
    "href": "http://stock.jrj.com.cn/2022/04/01172536247755.shtml",
    "datetime": "2022-04-01 17:25:03",
    "code": "300142"
  },
  {
    "title": "沃森生物将花不超4.2亿元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2022/03/28201035927604.shtml",
    "datetime": "2022-03-28 20:10:42",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司双价HPV疫苗获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/03/28171835893938.shtml",
    "datetime": "2022-03-28 17:18:14",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司双价HPV疫苗的药品批准证明文件已获签发",
    "href": "http://stock.jrj.com.cn/2022/03/24193334926939.shtml",
    "datetime": "2022-03-24 19:33:33",
    "code": "300142"
  },
  {
    "title": "沃森生物2021年净利4.28亿同比下滑57.36% 董事长李云春薪酬259.99万",
    "href": "http://stock.jrj.com.cn/2022/03/19051234848388.shtml",
    "datetime": "2022-03-19 05:12:50",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：DTaP-Hib四联疫苗获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/18210734847208.shtml",
    "datetime": "2022-03-18 21:07:59",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：上海泽润拟对玉溪泽润增资3.3亿元",
    "href": "http://stock.jrj.com.cn/2022/03/18210534847206.shtml",
    "datetime": "2022-03-18 21:05:59",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)拟回购300万-600万股公司股份",
    "href": "http://stock.jrj.com.cn/2022/03/18192434846722.shtml",
    "datetime": "2022-03-18 19:24:45",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)2021年度扣非净利润降17.33%至5.91亿元 拟10派0.27元",
    "href": "http://stock.jrj.com.cn/2022/03/18192234846695.shtml",
    "datetime": "2022-03-18 19:22:30",
    "code": "300142"
  },
  {
    "title": "蹭沃森生物mRNA疫苗热点的另类姿势：近岸蛋白疑似虚增原料酶收入，还涉嫌吹嘘原料酶生产能力……",
    "href": "http://stock.jrj.com.cn/ipo/2022/02/23113734442261.shtml",
    "datetime": "2022-02-23 11:37:35",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟对外捐赠23价肺炎疫苗",
    "href": "http://stock.jrj.com.cn/2022/02/14164534344892.shtml",
    "datetime": "2022-02-14 16:45:44",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：收到重组新型冠状病毒变异株疫苗(CHO细胞)境外临床试验伦理批件并获得CEPI资金资助",
    "href": "http://stock.jrj.com.cn/2022/02/08193534308637.shtml",
    "datetime": "2022-02-08 19:35:28",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)2021年度净利润预降54%–64%",
    "href": "http://stock.jrj.com.cn/2022/02/03145734279329.shtml",
    "datetime": "2022-02-03 14:57:55",
    "code": "300142"
  },
  {
    "title": "沃森生物2021年预计净利3.65亿-4.6亿同比下降54%-64% 新项目研发投入增加",
    "href": "http://stock.jrj.com.cn/2022/01/29093134254224.shtml",
    "datetime": "2022-01-29 09:31:52",
    "code": "300142"
  },
  {
    "title": "沃森生物：2021年净利同比预降54%–64%",
    "href": "http://stock.jrj.com.cn/2022/01/28224534251240.shtml",
    "datetime": "2022-01-28 22:45:04",
    "code": "300142"
  },
  {
    "title": "蓝帆医疗：预计2021年净利润为9-13亿元 外部因素导致业绩承压",
    "href": "http://stock.jrj.com.cn/2022/01/28223634251215.shtml",
    "datetime": "2022-01-28 22:36:11",
    "code": "300142"
  },
  {
    "title": "沃森生物聘任董少忠为副总裁 2021年第三季度公司净利4517.45万",
    "href": "http://stock.jrj.com.cn/2022/01/28211034248712.shtml",
    "datetime": "2022-01-28 21:10:52",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟与蓝鹊生物开展新冠病毒变异株mRNA疫苗的产品开发及商业化合作",
    "href": "http://stock.jrj.com.cn/2022/01/28163634243065.shtml",
    "datetime": "2022-01-28 16:36:11",
    "code": "300142"
  },
  {
    "title": "沃森生物：签署新冠病毒变异株mRNA疫苗技术开发及商业化合作协议",
    "href": "http://stock.jrj.com.cn/2022/01/28161834242946.shtml",
    "datetime": "2022-01-28 16:18:25",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：向中国妇女发展基金会捐赠现金1150万元",
    "href": "http://stock.jrj.com.cn/2021/12/28184134077295.shtml",
    "datetime": "2021-12-28 18:41:46",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司收到1项境外发明专利证书",
    "href": "http://stock.jrj.com.cn/2021/12/28183934077292.shtml",
    "datetime": "2021-12-28 18:39:02",
    "code": "300142"
  },
  {
    "title": "沃森生物：玉溪沃森拟投建多糖结合疫苗扩产扩能项目 总投资6.95亿元",
    "href": "http://stock.jrj.com.cn/2021/12/12221634000804.shtml",
    "datetime": "2021-12-12 22:16:14",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟投建多糖结合疫苗扩产扩能项目 总投资6.95亿元",
    "href": "http://stock.jrj.com.cn/2021/12/12173533999675.shtml",
    "datetime": "2021-12-12 17:35:15",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：终止筹划发行H股股票事项并撤回申请文件",
    "href": "http://stock.jrj.com.cn/2021/12/10205833996115.shtml",
    "datetime": "2021-12-10 20:58:47",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟在玉溪沃森疫苗产业园内投资建设多糖结合疫苗扩产扩能项目",
    "href": "http://stock.jrj.com.cn/2021/12/10201833995947.shtml",
    "datetime": "2021-12-10 20:18:28",
    "code": "300142"
  },
  {
    "title": "沃森生物启动新冠mRNA疫苗加强针IIIb期临床",
    "href": "http://stock.jrj.com.cn/2021/11/25115933918213.shtml",
    "datetime": "2021-11-25 11:59:53",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)连续第二日上涨 启动新冠mRNA疫苗加强针IIIb期临床",
    "href": "http://stock.jrj.com.cn/2021/11/25105933917964.shtml",
    "datetime": "2021-11-25 10:59:14",
    "code": "300142"
  },
  {
    "title": "外资罕见砸盘近120亿，医药股突然大爆发！120万元一针抗癌神药进入医保谈判，恒瑞医药、沃森生物狂飙！",
    "href": "http://stock.jrj.com.cn/2021/11/10162933831890.shtml",
    "datetime": "2021-11-10 16:29:35",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)一度逼近涨停 mRNA新冠疫苗加强针III期临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/11/10143933831534.shtml",
    "datetime": "2021-11-10 14:39:11",
    "code": "300142"
  },
  {
    "title": "A股疫苗股集体下挫 复星医药和沃森生物跌超5%",
    "href": "http://stock.jrj.com.cn/2021/11/08102133822277.shtml",
    "datetime": "2021-11-08 10:21:03",
    "code": "300142"
  },
  {
    "title": "股东减持留下“后遗症”，沃森生物实控人位置仍“空悬”",
    "href": "http://stock.jrj.com.cn/2021/10/30074033782290.shtml",
    "datetime": "2021-10-30 07:40:45",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)半日收跌4.27% Q3净利润同比下降87.92%",
    "href": "http://stock.jrj.com.cn/2021/10/29120433776256.shtml",
    "datetime": "2021-10-29 12:04:41",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：第三季度扣非净利润降61.34%至1.45亿元",
    "href": "http://stock.jrj.com.cn/2021/10/28174933770334.shtml",
    "datetime": "2021-10-28 17:49:56",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：ACYW135群脑膜炎球菌多糖结合疫苗获得Ⅲ期临床试验伦理审查意见书",
    "href": "http://stock.jrj.com.cn/2021/10/11173233673806.shtml",
    "datetime": "2021-10-11 17:32:37",
    "code": "300142"
  },
  {
    "title": "沃森生物跌5.57% 中信证券1个月前喊买入",
    "href": "http://stock.jrj.com.cn/2021/10/08180433658646.shtml",
    "datetime": "2021-10-08 18:04:00",
    "code": "300142"
  },
  {
    "title": "沃森生物跌6.07% 中信证券3周前喊买入目标价90元",
    "href": "http://stock.jrj.com.cn/2021/09/29182433537566.shtml",
    "datetime": "2021-09-29 18:24:00",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：刘俊辉及其配偶黄静合计持股比例被动降低至5%以下",
    "href": "http://stock.jrj.com.cn/2021/09/26205833516857.shtml",
    "datetime": "2021-09-26 20:58:16",
    "code": "300142"
  },
  {
    "title": "沃森生物跌6.27% 中信证券半个月前喊买入目标价90元",
    "href": "http://stock.jrj.com.cn/2021/09/22174533499567.shtml",
    "datetime": "2021-09-22 17:45:00",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：合作研发的新冠病毒mRNA疫苗获尼泊尔Ⅲ期临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/09/22160733499037.shtml",
    "datetime": "2021-09-22 16:07:03",
    "code": "300142"
  },
  {
    "title": "健帆生物、沃森生物等集体涨超9%，医疗ETF(159828) 涨近6%",
    "href": "http://stock.jrj.com.cn/2021/09/17133433450646.shtml",
    "datetime": "2021-09-17 13:34:08",
    "code": "300142"
  },
  {
    "title": "圣达生物、沃森生物、昊海生科涨超7%，生物医药ETF（512290）涨超2%",
    "href": "http://stock.jrj.com.cn/2021/09/17131233450598.shtml",
    "datetime": "2021-09-17 13:12:59",
    "code": "300142"
  },
  {
    "title": "沃森生物跌4.68% 中信证券一周前喊买入目标价90元",
    "href": "http://stock.jrj.com.cn/2021/09/15165333440080.shtml",
    "datetime": "2021-09-15 16:53:00",
    "code": "300142"
  },
  {
    "title": "康泰生物、沃森生物、乐普医疗跌超4%，科创创业ETF（588360）跌超1%",
    "href": "http://stock.jrj.com.cn/2021/09/15134133438992.shtml",
    "datetime": "2021-09-15 13:41:19",
    "code": "300142"
  },
  {
    "title": "沃森生物跌4.39% 中信证券一周前喊买入目标价90元",
    "href": "http://stock.jrj.com.cn/2021/09/13171533428909.shtml",
    "datetime": "2021-09-13 17:15:00",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：可行权的股票期权为2840万份",
    "href": "http://stock.jrj.com.cn/2021/09/12132133419782.shtml",
    "datetime": "2021-09-12 13:21:08",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：可行权的股票期权为739万份",
    "href": "http://stock.jrj.com.cn/2021/09/12131933419781.shtml",
    "datetime": "2021-09-12 13:19:21",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前有3个新冠疫苗产品 处于临床研究的不同阶段",
    "href": "http://stock.jrj.com.cn/2021/09/12071333419443.shtml",
    "datetime": "2021-09-12 07:13:54",
    "code": "300142"
  },
  {
    "title": "沃森生物跌7.96% 招商证券上月末给予审慎推荐评级",
    "href": "http://stock.jrj.com.cn/2021/09/02174433375012.shtml",
    "datetime": "2021-09-02 17:44:00",
    "code": "300142"
  },
  {
    "title": "沃森生物2021年半年度净利3.19亿元 同比净利增加419.09%",
    "href": "http://stock.jrj.com.cn/2021/08/27223033336646.shtml",
    "datetime": "2021-08-27 22:30:13",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：上海泽润在北京设立全资子公司 投建重组新型冠状病毒疫苗(CHO细胞)产业化项目",
    "href": "http://stock.jrj.com.cn/2021/08/27220433336428.shtml",
    "datetime": "2021-08-27 22:04:54",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)与蓝鹊生物共同开展呼吸道合胞病毒mRNA疫苗产品开发及商业化合作",
    "href": "http://stock.jrj.com.cn/2021/08/27215833336345.shtml",
    "datetime": "2021-08-27 21:58:37",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)与蓝鹊生物共同开展流感病毒mRNA疫苗产品开发及商业化合作",
    "href": "http://stock.jrj.com.cn/2021/08/27215633336336.shtml",
    "datetime": "2021-08-27 21:56:09",
    "code": "300142"
  },
  {
    "title": "沃森生物：上半年净利同比增419% 共同开展流感病毒mRNA疫苗的产品开发及商业化合作",
    "href": "http://stock.jrj.com.cn/2021/08/27215433336326.shtml",
    "datetime": "2021-08-27 21:54:09",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)上半年净利升419.09%至3.19亿元",
    "href": "http://stock.jrj.com.cn/2021/08/27215233336313.shtml",
    "datetime": "2021-08-27 21:52:18",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：739万份预留授予股票期权可行权",
    "href": "http://stock.jrj.com.cn/2021/08/16221133262819.shtml",
    "datetime": "2021-08-16 22:11:00",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：2840万份股票期权可行权",
    "href": "http://stock.jrj.com.cn/2021/08/16220933262807.shtml",
    "datetime": "2021-08-16 22:09:40",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟向银行申请综合授信及流动资金贷款合计10亿元",
    "href": "http://stock.jrj.com.cn/2021/07/28214333165920.shtml",
    "datetime": "2021-07-28 21:43:33",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：董事张建生辞职",
    "href": "http://stock.jrj.com.cn/2021/07/16194133108922.shtml",
    "datetime": "2021-07-16 19:41:43",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司上海泽润收到1项发明专利证书",
    "href": "http://stock.jrj.com.cn/2021/07/13171433089795.shtml",
    "datetime": "2021-07-13 17:14:04",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前共有7个疫苗产品（9个品规）生产上市销售",
    "href": "http://stock.jrj.com.cn/2021/06/24220332992170.shtml",
    "datetime": "2021-06-24 22:03:28",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司新冠疫苗目前处于临床试验阶段",
    "href": "http://stock.jrj.com.cn/2021/06/24194732991229.shtml",
    "datetime": "2021-06-24 19:47:35",
    "code": "300142"
  },
  {
    "title": "沃森生物：子公司玉溪沃森已按照《通知》规定积极配合完成了相关检查工作",
    "href": "http://stock.jrj.com.cn/2021/06/23133232982379.shtml",
    "datetime": "2021-06-23 13:32:45",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司23价肺炎球菌多糖疫苗获批在现有的包装形式“预灌封注射器”基础上增加“西林瓶”包装",
    "href": "http://stock.jrj.com.cn/2021/06/21222532972060.shtml",
    "datetime": "2021-06-21 22:25:33",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司已与摩洛哥合作方签署了13价肺炎结合疫苗在摩洛哥的经销协议",
    "href": "http://stock.jrj.com.cn/2021/06/21221232971982.shtml",
    "datetime": "2021-06-21 22:12:32",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司13价肺炎结合疫苗在摩洛哥的注册工作正在进行中",
    "href": "http://stock.jrj.com.cn/2021/06/21214332971816.shtml",
    "datetime": "2021-06-21 21:43:37",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：23价肺炎球菌多糖疫苗获批增加西林瓶包装剂型",
    "href": "http://stock.jrj.com.cn/2021/06/21165332970000.shtml",
    "datetime": "2021-06-21 16:53:55",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司和子公司上海泽润将积极配合审评审批的各项工作",
    "href": "http://stock.jrj.com.cn/2021/06/18203132956676.shtml",
    "datetime": "2021-06-18 20:31:11",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前已上市的7个疫苗产品（9个品规）的生产、批签发、销售和接种工作均正常开展",
    "href": "http://stock.jrj.com.cn/2021/06/11210732913962.shtml",
    "datetime": "2021-06-11 21:07:23",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：部分董事、高管向成都喜云转让137.5万股",
    "href": "http://stock.jrj.com.cn/2021/06/04181832875125.shtml",
    "datetime": "2021-06-04 18:18:22",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：因持股方式调整 董事长和副董事长向成都喜云转让共353.6747万股",
    "href": "http://stock.jrj.com.cn/2021/06/03155932869332.shtml",
    "datetime": "2021-06-03 15:59:34",
    "code": "300142"
  },
  {
    "title": "山东药玻：沃森生物是公司的客户 但目前无疫苗包装合作",
    "href": "http://stock.jrj.com.cn/2021/06/02191532864911.shtml",
    "datetime": "2021-06-02 19:15:13",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前已有7个疫苗产品（9个品规）生产上市销售",
    "href": "http://stock.jrj.com.cn/2021/06/01202532858986.shtml",
    "datetime": "2021-06-01 20:25:22",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前暂无对hiv进行研究相关计划",
    "href": "http://stock.jrj.com.cn/2021/05/31182532851427.shtml",
    "datetime": "2021-05-31 18:25:35",
    "code": "300142"
  },
  {
    "title": "20亿应收与10亿推广费成“隐患” 新疫苗能否助沃森生物重回巅峰",
    "href": "http://stock.jrj.com.cn/2021/05/31080132846943.shtml",
    "datetime": "2021-05-31 08:01:40",
    "code": "300142"
  },
  {
    "title": "沃森生物：合作研发的重组新冠疫苗获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/05/29102132838555.shtml",
    "datetime": "2021-05-29 10:21:04",
    "code": "300142"
  },
  {
    "title": "【公告抢先看】晚间重要公告：沃森生物重组新型冠状病毒疫苗获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/05/28174432835981.shtml",
    "datetime": "2021-05-28 17:44:30",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：合作研发的重组新型冠状病毒疫苗获药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/05/28161332835495.shtml",
    "datetime": "2021-05-28 16:13:41",
    "code": "300142"
  },
  {
    "title": "沃森生物：重组新型冠状病毒疫苗获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/05/28160732835479.shtml",
    "datetime": "2021-05-28 16:07:46",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：玉溪沃森拟申请4亿元综合授信及流动资金贷款",
    "href": "http://stock.jrj.com.cn/2021/05/27155332829970.shtml",
    "datetime": "2021-05-27 15:53:39",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司车间和厂房未受到地震影响",
    "href": "http://stock.jrj.com.cn/2021/05/26170532823839.shtml",
    "datetime": "2021-05-26 17:05:46",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)2020年度权益分派10派0.5元 股权登记日为5月18日",
    "href": "http://stock.jrj.com.cn/2021/05/12215832744324.shtml",
    "datetime": "2021-05-12 21:58:12",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司H股发行的相关工作在持续推进中",
    "href": "http://stock.jrj.com.cn/2021/05/10185932731177.shtml",
    "datetime": "2021-05-10 18:59:06",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司新冠mRNA疫苗产业化车间建设工作正在紧锣密鼓的进行中",
    "href": "http://stock.jrj.com.cn/2021/05/10185232731138.shtml",
    "datetime": "2021-05-10 18:52:56",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司mRNA疫苗临床试验和产业化的相关工作与九价HPV疫苗临床试验之间没有直接关系",
    "href": "http://stock.jrj.com.cn/2021/05/10184532731090.shtml",
    "datetime": "2021-05-10 18:45:31",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：股东刘俊辉解除质押合计2625万股",
    "href": "http://stock.jrj.com.cn/2021/05/07194332712827.shtml",
    "datetime": "2021-05-07 19:43:18",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司收到一项由巴西专利局颁发的发明专利证书",
    "href": "http://stock.jrj.com.cn/2021/05/07194132712819.shtml",
    "datetime": "2021-05-07 19:41:15",
    "code": "300142"
  },
  {
    "title": "疫苗股重挫，复星医药跌停，康希诺、沃森生物跌超14％，港股疫苗概念股同步大跌，海通证券：无需过分担心",
    "href": "http://stock.jrj.com.cn/2021/05/06101532699978.shtml",
    "datetime": "2021-05-06 10:15:41",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：签署针对通用流感病毒的siRNA药物的抗病毒核酸干扰药物合作开发和许可协议",
    "href": "http://stock.jrj.com.cn/2021/04/27202632465233.shtml",
    "datetime": "2021-04-27 20:26:05",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：签署13价肺炎球菌多糖结合疫苗海外销售协议",
    "href": "http://stock.jrj.com.cn/2021/04/27202232465223.shtml",
    "datetime": "2021-04-27 20:22:19",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)一季度扣非净利润7502.39万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/04/27201932465209.shtml",
    "datetime": "2021-04-27 20:19:53",
    "code": "300142"
  },
  {
    "title": "沃森生物：签署13价肺炎球菌多糖结合疫苗海外销售协议",
    "href": "http://stock.jrj.com.cn/2021/04/27195932465097.shtml",
    "datetime": "2021-04-27 19:59:48",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司与艾博生物合作研发的2个疫苗产品的临床和研发工作均在按计划正常推进中",
    "href": "http://stock.jrj.com.cn/2021/04/20181332411121.shtml",
    "datetime": "2021-04-20 18:13:36",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前共有7个疫苗产品生产上市销售",
    "href": "http://stock.jrj.com.cn/2021/04/20180632411037.shtml",
    "datetime": "2021-04-20 18:06:25",
    "code": "300142"
  },
  {
    "title": "沃森生物年报被交易所问询 虚增业绩再添新证据？",
    "href": "http://stock.jrj.com.cn/2021/04/15080332377546.shtml",
    "datetime": "2021-04-15 08:03:00",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前暂无艾滋病疫苗研发计划",
    "href": "http://stock.jrj.com.cn/2021/04/14191732373167.shtml",
    "datetime": "2021-04-14 19:17:49",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司13价肺炎结合疫苗的有效期为2年",
    "href": "http://stock.jrj.com.cn/2021/04/14182332372893.shtml",
    "datetime": "2021-04-14 18:23:17",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司H股发行事宜正在按计划持续推进中",
    "href": "http://stock.jrj.com.cn/2021/04/09200232344212.shtml",
    "datetime": "2021-04-09 20:02:34",
    "code": "300142"
  },
  {
    "title": "沃森生物2021年第一季度预计净利2860万-3400万 疫苗产品销售量和销售收入同比增加",
    "href": "http://stock.jrj.com.cn/2021/04/09090832339033.shtml",
    "datetime": "2021-04-09 09:08:26",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)一季度预盈2860万-3400万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/04/08202932333842.shtml",
    "datetime": "2021-04-08 20:29:11",
    "code": "300142"
  },
  {
    "title": "沃森生物：目前公司Hib疫苗（西林瓶）的中标价约为85元/瓶左右",
    "href": "http://stock.jrj.com.cn/2021/03/29192332242792.shtml",
    "datetime": "2021-03-29 19:23:24",
    "code": "300142"
  },
  {
    "title": "沃森生物2020年净利增长606.6% 董事长李云春薪酬144.98万",
    "href": "http://stock.jrj.com.cn/2021/03/26192332224047.shtml",
    "datetime": "2021-03-26 19:23:03",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟调整“玉溪沃森疫苗产业园三期工程项目”达到预定可使用状态时间",
    "href": "http://stock.jrj.com.cn/2021/03/26145132222552.shtml",
    "datetime": "2021-03-26 14:51:20",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟终止并注销珠海横琴沃森投资基金",
    "href": "http://stock.jrj.com.cn/2021/03/26144832222546.shtml",
    "datetime": "2021-03-26 14:48:36",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)2020年度净利润升606.6%至10.03亿元 拟10派0.5元",
    "href": "http://stock.jrj.com.cn/2021/03/26144432222521.shtml",
    "datetime": "2021-03-26 14:44:39",
    "code": "300142"
  },
  {
    "title": "沃森生物年报：自主疫苗发力净利增逾六倍 将持续深入推进全面国际化战略",
    "href": "http://stock.jrj.com.cn/2021/03/26133432222274.shtml",
    "datetime": "2021-03-26 13:34:46",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前没有脱发疫苗研究项目",
    "href": "http://stock.jrj.com.cn/2021/03/08163132091470.shtml",
    "datetime": "2021-03-08 16:31:00",
    "code": "300142"
  },
  {
    "title": "沃森生物跌6% 去年申万宏源中银证券等山顶唱多",
    "href": "http://stock.jrj.com.cn/2021/03/04181932072164.shtml",
    "datetime": "2021-03-04 18:19:00",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：收到一项发明专利证书 为一种同时制备两种单克隆抗体的方法",
    "href": "http://stock.jrj.com.cn/2021/03/01181432051489.shtml",
    "datetime": "2021-03-01 18:14:56",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：发行H股申请材料获证监会受理",
    "href": "http://stock.jrj.com.cn/2021/02/08164731870682.shtml",
    "datetime": "2021-02-08 16:47:28",
    "code": "300142"
  },
  {
    "title": "港股IPO|沃森生物向证监会递交境外审批材料，拟香港上市",
    "href": "http://stock.jrj.com.cn/2021/02/02091831834598.shtml",
    "datetime": "2021-02-02 09:18:30",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司始终专注于前沿技术和新产品的研发和布局",
    "href": "http://stock.jrj.com.cn/2021/02/01073531826242.shtml",
    "datetime": "2021-02-01 07:35:30",
    "code": "300142"
  },
  {
    "title": "[互动]沃森生物：公司13价肺炎结合疫苗不存在销售价格低于中标价情况",
    "href": "http://stock.jrj.com.cn/2021/01/30152231815045.shtml",
    "datetime": "2021-01-30 15:22:56",
    "code": "300142"
  },
  {
    "title": "沃森生物2020年业绩预增，净利润同比上涨约600%",
    "href": "http://stock.jrj.com.cn/2021/01/28132931800635.shtml",
    "datetime": "2021-01-28 13:29:54",
    "code": "300142"
  },
  {
    "title": "沃森生物业绩预告：持续加大疫苗市场拓展力度 2020年净利预增590%至620%",
    "href": "http://stock.jrj.com.cn/2021/01/28100731800019.shtml",
    "datetime": "2021-01-28 10:07:44",
    "code": "300142"
  },
  {
    "title": "沃森生物2020年预计净利9.8亿-10.22亿增长590%–620% 疫苗产量增长",
    "href": "http://stock.jrj.com.cn/2021/01/28091931799591.shtml",
    "datetime": "2021-01-28 09:19:18",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司目前拥有已上市的自主疫苗品种7个",
    "href": "http://stock.jrj.com.cn/2021/01/06201631643394.shtml",
    "datetime": "2021-01-06 20:16:22",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟聘请安永为H股首发并在香港联交所主板上市的申报会计师",
    "href": "http://stock.jrj.com.cn/2021/01/06195731643318.shtml",
    "datetime": "2021-01-06 19:57:00",
    "code": "300142"
  },
  {
    "title": "沃森生物：二价HPV疫苗注册上市许可申请工作获重要进展",
    "href": "http://stock.jrj.com.cn/2020/12/31171931613182.shtml",
    "datetime": "2020-12-31 17:19:45",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：二价HPV疫苗收到注册现场核查通知",
    "href": "http://stock.jrj.com.cn/2020/12/31171431613170.shtml",
    "datetime": "2020-12-31 17:14:38",
    "code": "300142"
  },
  {
    "title": "A股异动丨沃森生物(300142.SZ)大涨近7% 新冠疫苗基地落户大兴 明年年中大规模生产",
    "href": "http://stock.jrj.com.cn/2020/12/28095331584675.shtml",
    "datetime": "2020-12-28 09:53:59",
    "code": "300142"
  },
  {
    "title": "[沃森生物]又一支“国家队”新冠疫苗将大规模生产",
    "href": "http://stock.jrj.com.cn/2020/12/28000031585158.shtml",
    "datetime": "2020-12-28 00:00:00",
    "code": "300142"
  },
  {
    "title": "[沃森生物](医卫)我国mRNA新冠病毒疫苗生产车间在云南玉溪奠基",
    "href": "http://stock.jrj.com.cn/2020/12/23000031553658.shtml",
    "datetime": "2020-12-23 00:00:00",
    "code": "300142"
  },
  {
    "title": "沃森生物：放弃上海泽润股权优先购买权 聚焦重磅产品保持领先地位",
    "href": "http://stock.jrj.com.cn/2020/12/21192231538487.shtml",
    "datetime": "2020-12-21 19:22:07",
    "code": "300142"
  },
  {
    "title": "沃森生物：临时股东大会审议通过放弃泽润生物股权优先购买权暨关联交易的议案",
    "href": "http://stock.jrj.com.cn/2020/12/21182431537697.shtml",
    "datetime": "2020-12-21 18:24:43",
    "code": "300142"
  },
  {
    "title": "受益国内首个mRNA新冠疫苗生产车间奠基 沃森生物今日股价涨约7%",
    "href": "http://stock.jrj.com.cn/2020/12/21152731536233.shtml",
    "datetime": "2020-12-21 15:27:16",
    "code": "300142"
  },
  {
    "title": "中国首个mRNA新冠疫苗生产车间奠基 沃森生物午后异动拉升一度涨超9%",
    "href": "http://stock.jrj.com.cn/2020/12/21135731535555.shtml",
    "datetime": "2020-12-21 13:57:25",
    "code": "300142"
  },
  {
    "title": "沃森生物曾两度扮演“白衣骑士”接盘石油富豪资产",
    "href": "http://stock.jrj.com.cn/2020/12/18162131518916.shtml",
    "datetime": "2020-12-18 16:21:10",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司各项生产经营和管理工作均在正常开展",
    "href": "http://stock.jrj.com.cn/2020/12/17163431509911.shtml",
    "datetime": "2020-12-17 16:34:19",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：子公司于近日获得政府补助资金1000万元",
    "href": "http://stock.jrj.com.cn/2020/12/15200231496320.shtml",
    "datetime": "2020-12-15 20:02:50",
    "code": "300142"
  },
  {
    "title": "沃森生物4个月市值蒸发939亿 申万宏源中银等山顶唱多",
    "href": "http://stock.jrj.com.cn/2020/12/14180431488165.shtml",
    "datetime": "2020-12-14 18:04:00",
    "code": "300142"
  },
  {
    "title": "分众传媒跌停主力分歧大 沃森生物遭弃创新低",
    "href": "http://stock.jrj.com.cn/2020/12/13075131473724.shtml",
    "datetime": "2020-12-13 07:51:56",
    "code": "300142"
  },
  {
    "title": "分众传媒跌停主力分歧大 沃森生物遭弃再创新低",
    "href": "http://stock.jrj.com.cn/2020/12/12100931470272.shtml",
    "datetime": "2020-12-12 10:09:04",
    "code": "300142"
  },
  {
    "title": "沃森生物被指“贱卖”优质资产背后：泰格医药和北大系旧将浮出水面",
    "href": "http://stock.jrj.com.cn/2020/12/11071631462216.shtml",
    "datetime": "2020-12-11 07:16:36",
    "code": "300142"
  },
  {
    "title": "信心难以修复！86页、41页“小作文”陈情后 沃森生物还是跌了",
    "href": "http://stock.jrj.com.cn/2020/12/09132431448177.shtml",
    "datetime": "2020-12-09 13:24:20",
    "code": "300142"
  },
  {
    "title": "沃森生物回复云南证监局：转让上海泽润股权有利于公司的长远发展",
    "href": "http://stock.jrj.com.cn/2020/12/09075631445758.shtml",
    "datetime": "2020-12-09 07:56:16",
    "code": "300142"
  },
  {
    "title": "沃森生物暂停出售子公司股权背后：全力冲击新冠疫苗",
    "href": "http://stock.jrj.com.cn/2020/12/09000531443920.shtml",
    "datetime": "2020-12-09 00:05:50",
    "code": "300142"
  },
  {
    "title": "沃森生物：本次转让不存在损害上市公司和中小投资者利益的行为",
    "href": "http://stock.jrj.com.cn/2020/12/08220131443374.shtml",
    "datetime": "2020-12-08 22:01:12",
    "code": "300142"
  },
  {
    "title": "沃森生物回复关注函：不存在公司仅因激励为由而放弃上海泽润控制权的行为",
    "href": "http://stock.jrj.com.cn/2020/12/08210431443040.shtml",
    "datetime": "2020-12-08 21:04:02",
    "code": "300142"
  },
  {
    "title": "7日放量跌停后 沃森生物股价8日小幅低开后剧烈震荡",
    "href": "http://stock.jrj.com.cn/2020/12/08095431437416.shtml",
    "datetime": "2020-12-08 09:54:06",
    "code": "300142"
  },
  {
    "title": "两融余额刷新五年新高 沃森生物融资盘流入7亿排在首位",
    "href": "http://stock.jrj.com.cn/2020/12/08093631437264.shtml",
    "datetime": "2020-12-08 09:36:41",
    "code": "300142"
  },
  {
    "title": "被问询后取消资产转让 沃森生物身陷“信披门”",
    "href": "http://stock.jrj.com.cn/2020/12/08074031436363.shtml",
    "datetime": "2020-12-08 07:40:28",
    "code": "300142"
  },
  {
    "title": "居然是一个逻辑：沃森生物持续下跌 茅台不断创新高",
    "href": "http://stock.jrj.com.cn/2020/12/08073531436332.shtml",
    "datetime": "2020-12-08 07:35:30",
    "code": "300142"
  },
  {
    "title": "沃森生物“卖子”急刹车：转让动机、交易估值皆存疑 “故事大王”不讲武德好多年",
    "href": "http://stock.jrj.com.cn/2020/12/08072331436240.shtml",
    "datetime": "2020-12-08 07:23:26",
    "code": "300142"
  },
  {
    "title": "央视专访沃森生物董事长！上市公司贱卖核心资产？11.4亿元到底咋定的？",
    "href": "http://stock.jrj.com.cn/2020/12/08070131435673.shtml",
    "datetime": "2020-12-08 07:01:41",
    "code": "300142"
  },
  {
    "title": "沃森生物“贱卖”背后涉嫌利益输送？",
    "href": "http://stock.jrj.com.cn/2020/12/08011431434392.shtml",
    "datetime": "2020-12-08 01:14:01",
    "code": "300142"
  },
  {
    "title": "被问询后取消资产转让 沃森生物身陷“信披门”",
    "href": "http://stock.jrj.com.cn/2020/12/07204031462547.shtml",
    "datetime": "2020-12-07 20:40:00",
    "code": "300142"
  },
  {
    "title": "【龙虎榜】沃森生物12月7日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/12/07180231431860.shtml",
    "datetime": "2020-12-07 18:02:20",
    "code": "300142"
  },
  {
    "title": "龙虎榜：方新侠回吐20%利润仓皇离场 沃森生物“被骂” 机构外资抛售近4亿",
    "href": "http://stock.jrj.com.cn/hotstock/2020/12/07175131431766.shtml",
    "datetime": "2020-12-07 17:51:38",
    "code": "300142"
  },
  {
    "title": "昔日涨逾20倍沃森生物大跌20% 逾百只基金持仓市值缩水近10亿",
    "href": "http://stock.jrj.com.cn/2020/12/07174431431574.shtml",
    "datetime": "2020-12-07 17:44:20",
    "code": "300142"
  },
  {
    "title": "沃森生物近百亿成交跌停，中水渔业地天板带动情绪修复",
    "href": "http://stock.jrj.com.cn/invest/2020/12/07173331431523.shtml",
    "datetime": "2020-12-07 17:33:27",
    "code": "300142"
  },
  {
    "title": "【资本60秒】沃森\"贱卖\"资产紧急撤摊 市值半日蒸发逾100亿！",
    "href": "http://stock.jrj.com.cn/2020/12/07173231431513.shtml",
    "datetime": "2020-12-07 17:32:01",
    "code": "300142"
  },
  {
    "title": "沃森生物“神操作”：核心子公司收获期前放弃股权 接盘者竟都有“泰格系”",
    "href": "http://stock.jrj.com.cn/2020/12/07164531431158.shtml",
    "datetime": "2020-12-07 16:45:42",
    "code": "300142"
  },
  {
    "title": "沃森生物欲卖上海泽润股权背后：HPV疫苗赛道玩家超20家，产品上市至少再投10亿",
    "href": "http://stock.jrj.com.cn/2020/12/07162931430947.shtml",
    "datetime": "2020-12-07 16:29:51",
    "code": "300142"
  },
  {
    "title": "【盘面全览12-07】贵州茅台又创新高 社区团购概念硝烟再起！",
    "href": "http://stock.jrj.com.cn/2020/12/07160531430519.shtml",
    "datetime": "2020-12-07 16:05:55",
    "code": "300142"
  },
  {
    "title": "沃森生物跌停:中泰证券资管持股 中银证券刚研报唱多",
    "href": "http://stock.jrj.com.cn/2020/12/07160031430578.shtml",
    "datetime": "2020-12-07 16:00:00",
    "code": "300142"
  },
  {
    "title": "深交所灵魂提问！贱卖核心资产的上市公司“紧急改口”：先不卖了！",
    "href": "http://stock.jrj.com.cn/2020/12/07154031430234.shtml",
    "datetime": "2020-12-07 15:40:35",
    "code": "300142"
  },
  {
    "title": "【午盘速递12.7】三大指数低位震荡 水产养殖概念逆市上涨！",
    "href": "http://stock.jrj.com.cn/2020/12/07115131428642.shtml",
    "datetime": "2020-12-07 11:51:23",
    "code": "300142"
  },
  {
    "title": "刚刚，20%跌停！“紧急改口”也挡不住暴跌",
    "href": "http://stock.jrj.com.cn/2020/12/07114631428576.shtml",
    "datetime": "2020-12-07 11:46:35",
    "code": "300142"
  },
  {
    "title": "沃森生物出尔反尔的代价：叫停出售HPV疫苗后盘中跌停 市值蒸发130亿",
    "href": "http://stock.jrj.com.cn/2020/12/07104031428433.shtml",
    "datetime": "2020-12-07 10:40:46",
    "code": "300142"
  },
  {
    "title": "沃森生物触及跌停成交额超40亿元 总市值蒸发逾140亿元",
    "href": "http://stock.jrj.com.cn/2020/12/07095031427565.shtml",
    "datetime": "2020-12-07 09:50:01",
    "code": "300142"
  },
  {
    "title": "开盘：沪指涨0.06%创业板指跌0.37% 沃森生物大跌近18%",
    "href": "http://stock.jrj.com.cn/2020/12/07092831427251.shtml",
    "datetime": "2020-12-07 09:28:55",
    "code": "300142"
  },
  {
    "title": "沃森生物跌17.81% 公司暂不将转让上海泽润股权议案提交股东大会审议",
    "href": "http://stock.jrj.com.cn/2020/12/07092731427244.shtml",
    "datetime": "2020-12-07 09:27:09",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：取消审议泽润股权转让及增资议案",
    "href": "http://stock.jrj.com.cn/2020/12/07085331426999.shtml",
    "datetime": "2020-12-07 08:53:51",
    "code": "300142"
  },
  {
    "title": "沃森生物：暂不将转让上海泽润股权议案提交股东大会审议",
    "href": "http://stock.jrj.com.cn/2020/12/07080131426402.shtml",
    "datetime": "2020-12-07 08:01:24",
    "code": "300142"
  },
  {
    "title": "[加急]贱卖核心资产 700亿牛股陷“电话会风波” 交易所火速发函 受益者竟是另一家上市公司 12万股东煎熬",
    "href": "http://stock.jrj.com.cn/2020/12/07075231426332.shtml",
    "datetime": "2020-12-07 07:52:01",
    "code": "300142"
  },
  {
    "title": "创业板第九大权重股与投资者怼上！监管质疑：是否存在利益输送？",
    "href": "http://stock.jrj.com.cn/2020/12/07072031426139.shtml",
    "datetime": "2020-12-07 07:20:25",
    "code": "300142"
  },
  {
    "title": "贱卖？利益输送？机构投资者集体“炸锅”的电话会后 交易所关注函到了！",
    "href": "http://stock.jrj.com.cn/2020/12/07071031426079.shtml",
    "datetime": "2020-12-07 07:10:10",
    "code": "300142"
  },
  {
    "title": "核心资产转让合理性受拷问 沃森生物电话会风波未平又收关注函",
    "href": "http://stock.jrj.com.cn/2020/12/07054631424842.shtml",
    "datetime": "2020-12-07 05:46:05",
    "code": "300142"
  },
  {
    "title": "子公司股权转让疑点多 沃森生物遭追问",
    "href": "http://stock.jrj.com.cn/2020/12/07004731421347.shtml",
    "datetime": "2020-12-07 00:47:21",
    "code": "300142"
  },
  {
    "title": "机构投资者集体“炸锅”的电话会后 交易所关注函到了",
    "href": "http://stock.jrj.com.cn/2020/12/06210631419973.shtml",
    "datetime": "2020-12-06 21:06:05",
    "code": "300142"
  },
  {
    "title": "沃森生物因转让上海泽润控制权收深交所关注函",
    "href": "http://stock.jrj.com.cn/2020/12/06145731418219.shtml",
    "datetime": "2020-12-06 14:57:45",
    "code": "300142"
  },
  {
    "title": "“你们知道因果报应吗 ？”核心HPV疫苗上市前被指大幅贱卖，机构投资者愤怒质问，电话会炸锅",
    "href": "http://stock.jrj.com.cn/2020/12/06085731417010.shtml",
    "datetime": "2020-12-06 08:57:55",
    "code": "300142"
  },
  {
    "title": "周末炸锅！700亿疫苗股被指贱卖资产 受益者竟是这家巨头",
    "href": "http://stock.jrj.com.cn/2020/12/06070231416735.shtml",
    "datetime": "2020-12-06 07:02:25",
    "code": "300142"
  },
  {
    "title": "放弃HPV疫苗子公司控股权引争议 沃森生物董事长李云春：蛋糕做大了仍能分享收益",
    "href": "http://stock.jrj.com.cn/2020/12/05175731414527.shtml",
    "datetime": "2020-12-05 17:57:43",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：拟转让上海泽润部分股权 预计将产生净利润约11.8亿-12.8亿元",
    "href": "http://stock.jrj.com.cn/2020/12/04214831411033.shtml",
    "datetime": "2020-12-04 21:48:18",
    "code": "300142"
  },
  {
    "title": "[沃森生物]沃森生物黄镇当选“全国劳动模范”",
    "href": "http://stock.jrj.com.cn/2020/11/26000031353155.shtml",
    "datetime": "2020-11-26 00:00:00",
    "code": "300142"
  },
  {
    "title": "沃森生物：合作研发的新型冠状病毒mRNA疫苗处于一期临床试验阶段",
    "href": "http://stock.jrj.com.cn/2020/11/21152831328550.shtml",
    "datetime": "2020-11-21 15:28:07",
    "code": "300142"
  },
  {
    "title": "股权激励难抵市值缩水700亿 沃森生物遭遇机构与股东组团减持",
    "href": "http://stock.jrj.com.cn/2020/11/12070531264799.shtml",
    "datetime": "2020-11-12 07:05:02",
    "code": "300142"
  },
  {
    "title": "A股异动丨沃森生物(300142.SZ)涨超6% 拟推7260万份股票期权激励计划",
    "href": "http://stock.jrj.com.cn/2020/11/04100231213641.shtml",
    "datetime": "2020-11-04 10:02:49",
    "code": "300142"
  },
  {
    "title": "沃森生物股价腰斩后：13价肺炎球菌疫苗、赴港上市引关注",
    "href": "http://stock.jrj.com.cn/2020/10/29193931158916.shtml",
    "datetime": "2020-10-29 19:39:23",
    "code": "300142"
  },
  {
    "title": "HPV疫苗紧俏 沃森生物、万泰生物等企业领跑国产赛道",
    "href": "http://stock.jrj.com.cn/2020/10/27200231144044.shtml",
    "datetime": "2020-10-27 20:02:06",
    "code": "300142"
  },
  {
    "title": "沃森生物三季度净利3.74亿增近10倍 自主疫苗贡献97%收入研发费用率达9.81%",
    "href": "http://stock.jrj.com.cn/2020/10/22074431105927.shtml",
    "datetime": "2020-10-22 07:44:39",
    "code": "300142"
  },
  {
    "title": "中信建投：沃森生物13价放量带动业绩超预期增长 拟港股IPO加大研发投入",
    "href": "http://stock.jrj.com.cn/2020/10/22073931105759.shtml",
    "datetime": "2020-10-22 07:39:02",
    "code": "300142"
  },
  {
    "title": "沃森生物谋划H股上市 意在推进国际化战略",
    "href": "http://stock.jrj.com.cn/2020/10/22032131104122.shtml",
    "datetime": "2020-10-22 03:21:50",
    "code": "300142"
  },
  {
    "title": "荣昌生物今日正式通过港交所聆讯 沃森生物前三季度归母净利润增长超260％ | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/10/21185731101986.shtml",
    "datetime": "2020-10-21 18:57:29",
    "code": "300142"
  },
  {
    "title": "沃森生物2020年前三季度净利4.35亿增长261.79% 财务费用下滑",
    "href": "http://stock.jrj.com.cn/2020/10/20214831094673.shtml",
    "datetime": "2020-10-20 21:48:03",
    "code": "300142"
  },
  {
    "title": "沃森生物：重磅产品持续发力 前三季度各项指标强势增长",
    "href": "http://stock.jrj.com.cn/2020/10/20214131094610.shtml",
    "datetime": "2020-10-20 21:41:09",
    "code": "300142"
  },
  {
    "title": "【公告抢先看】晚间重要公告：蓝盾股份在“量子科技”领域未进行市场业务开展、沃森生物拟在联交所主板上市",
    "href": "http://stock.jrj.com.cn/2020/10/20200331094109.shtml",
    "datetime": "2020-10-20 20:03:26",
    "code": "300142"
  },
  {
    "title": "沃森生物：拟发行H股并在香港联合交易所主板上市",
    "href": "http://stock.jrj.com.cn/2020/10/20194631093901.shtml",
    "datetime": "2020-10-20 19:46:49",
    "code": "300142"
  },
  {
    "title": "（互动易答问）沃森生物：公司13价肺炎结合疫苗生产和销售工作均正常开展",
    "href": "http://stock.jrj.com.cn/2020/10/19192131085245.shtml",
    "datetime": "2020-10-19 19:21:37",
    "code": "300142"
  },
  {
    "title": "沃森生物(300142.SZ)：参股公司嘉和生物10月7日正式登陆港交所",
    "href": "http://stock.jrj.com.cn/2020/10/11193031019807.shtml",
    "datetime": "2020-10-11 19:30:37",
    "code": "300142"
  },
  {
    "title": "沃森生物2名股东合计减持1147.08万股 套现约3.95亿元",
    "href": "http://stock.jrj.com.cn/2020/10/09212531012554.shtml",
    "datetime": "2020-10-09 21:25:35",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司已上市的7个疫苗产品（9个品规）的生产和销售工作均在正常开展",
    "href": "http://stock.jrj.com.cn/2020/10/09181731011480.shtml",
    "datetime": "2020-10-09 18:17:59",
    "code": "300142"
  },
  {
    "title": "沃森生物：2价HPV已进入生产申报阶段，获批后即可上市",
    "href": "http://stock.jrj.com.cn/2020/09/18132530776361.shtml",
    "datetime": "2020-09-18 13:25:42",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司13价肺炎结合疫苗截至9月11日批签发量为288万剂",
    "href": "http://stock.jrj.com.cn/2020/09/18130430776254.shtml",
    "datetime": "2020-09-18 13:04:29",
    "code": "300142"
  },
  {
    "title": "沃森生物：设计年产能可满足产品正式上市一段时期后放量增长的需求",
    "href": "http://stock.jrj.com.cn/2020/09/18123330776124.shtml",
    "datetime": "2020-09-18 12:33:35",
    "code": "300142"
  },
  {
    "title": "沃森生物：疫苗销售周期根据各个地方疾控中心招标及发货要求有不同时间周期",
    "href": "http://stock.jrj.com.cn/2020/09/18123230776121.shtml",
    "datetime": "2020-09-18 12:32:40",
    "code": "300142"
  },
  {
    "title": "沃森生物：13价肺炎结合疫苗 截止到9月上旬 24个省份已中标 22个省份已实现供货销售",
    "href": "http://stock.jrj.com.cn/2020/09/18123230776120.shtml",
    "datetime": "2020-09-18 12:32:31",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司将加大国际新市场的开拓力度持续筹备已有产品的WHO预认证工作",
    "href": "http://stock.jrj.com.cn/2020/09/18120830775944.shtml",
    "datetime": "2020-09-18 12:08:11",
    "code": "300142"
  },
  {
    "title": "沃森生物：2020年上半年公司二类疫苗销售均有不同增长",
    "href": "http://stock.jrj.com.cn/2020/09/18120630775932.shtml",
    "datetime": "2020-09-18 12:06:06",
    "code": "300142"
  },
  {
    "title": "沃森生物：13价肺炎结合疫苗截止到9月上旬 24个省份已中标 22个省份已实现供货销售 并形成销售收入",
    "href": "http://stock.jrj.com.cn/2020/09/18115630775843.shtml",
    "datetime": "2020-09-18 11:56:47",
    "code": "300142"
  },
  {
    "title": "沃森生物：公司13价肺炎结合疫苗24个省份已中标",
    "href": "http://stock.jrj.com.cn/2020/09/18115230775835.shtml",
    "datetime": "2020-09-18 11:52:54",
    "code": "300142"
  },
  {
    "title": "沃森生物：目前公司13价肺炎结合疫苗尚未获得国外订单",
    "href": "http://stock.jrj.com.cn/2020/09/18114230775771.shtml",
    "datetime": "2020-09-18 11:42:02",
    "code": "300142"
  },
  {
    "title": "乘风破浪的疫苗之王净利润下降三成 沃森生物下半场将如何“力挽狂澜”",
    "href": "http://stock.jrj.com.cn/2020/08/27071930600959.shtml",
    "datetime": "2020-08-27 07:19:13",
    "code": "300142"
  },
  {
    "title": "沃森生物 1500亿 美丽的泡沫？",
    "href": "http://stock.jrj.com.cn/2020/08/21100430555593.shtml",
    "datetime": "2020-08-21 10:04:25",
    "code": "300142"
  },
  {
    "title": "【龙虎榜】沃森生物8月19日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/19180630540281.shtml",
    "datetime": "2020-08-19 18:06:06",
    "code": "300142"
  },
  {
    "title": "疫苗概念股沃森生物跌停 三机构席位卖出2.6亿元",
    "href": "http://stock.jrj.com.cn/2020/08/19173330539978.shtml",
    "datetime": "2020-08-19 17:33:00",
    "code": "300142"
  },
  {
    "title": "千亿市值沃森生物跌停日成交41亿 中银证券刚喊增持",
    "href": "http://stock.jrj.com.cn/2020/08/19163030539221.shtml",
    "datetime": "2020-08-19 16:30:00",
    "code": "300142"
  },
  {
    "title": "拳头疫苗产品上市带动销售增长 沃森生物PCV13疫苗批签发已占三成市场",
    "href": "http://stock.jrj.com.cn/2020/08/17204430521287.shtml",
    "datetime": "2020-08-17 20:44:43",
    "code": "300142"
  },
  {
    "title": "沃森生物2020年上半年净利6149.11万下滑27.6% 营业成本同比增长",
    "href": "http://stock.jrj.com.cn/2020/08/15114130503967.shtml",
    "datetime": "2020-08-15 11:41:55",
    "code": "300142"
  },
  {
    "title": "【龙虎榜】沃森生物8月6日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/06180730443143.shtml",
    "datetime": "2020-08-06 18:07:30",
    "code": "300142"
  },
  {
    "title": "【龙虎榜】沃森生物8月5日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/05180830434326.shtml",
    "datetime": "2020-08-05 18:08:14",
    "code": "300142"
  },
  {
    "title": "沃森生物午后涨停！封单逾6万手",
    "href": "http://stock.jrj.com.cn/2020/08/05135730431799.shtml",
    "datetime": "2020-08-05 13:57:53",
    "code": "300142"
  },
  {
    "title": "[互动]沃森生物：与艾博生物合作研发的新冠疫苗临床试验正常推进中",
    "href": "http://stock.jrj.com.cn/2020/08/02072630400579.shtml",
    "datetime": "2020-08-02 07:26:32",
    "code": "300142"
  },
  {
    "title": "【龙虎榜】沃森生物7月31日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/07/31180230395225.shtml",
    "datetime": "2020-07-31 18:02:50",
    "code": "300142"
  },
  {
    "title": "沃森生物：2020年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/07/14031030229193.shtml",
    "datetime": "2020-07-14 03:10:04",
    "code": "300142"
  },
  {
    "title": "沃森生物2020年上半年预计净利6100万元-6600万元同比下降 股票期权激励分摊费用较上期增加",
    "href": "http://stock.jrj.com.cn/2020/07/13213130228079.shtml",
    "datetime": "2020-07-13 21:31:12",
    "code": "300142"
  },
  {
    "title": "沃森生物：合作研发的新型冠状病毒mRNA疫苗获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2020/06/28185030070994.shtml",
    "datetime": "2020-06-28 18:50:41",
    "code": "300142"
  },
  {
    "title": "沃森生物：中国首个mRNA新型冠状病毒疫苗获批进入临床试验阶段",
    "href": "http://stock.jrj.com.cn/2020/06/28174930070095.shtml",
    "datetime": "2020-06-28 17:49:41",
    "code": "300142"
  },
  {
    "title": "重磅产品再下一城 沃森生物二价HPV疫苗注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2020/06/16113929936187.shtml",
    "datetime": "2020-06-16 11:39:34",
    "code": "300142"
  },
  {
    "title": "【公告解读】沃森生物：子公司二价HPV疫苗申请新药生产的药品注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2020/06/15190029929650.shtml",
    "datetime": "2020-06-15 19:00:36",
    "code": "300142"
  },
  {
    "title": "沃森生物子公司二价HPV疫苗申请新药生产的药品注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2020/06/15182029929455.shtml",
    "datetime": "2020-06-15 18:20:18",
    "code": "300142"
  },
  {
    "title": "沃森生物：子公司二价HPV疫苗申请新药生产的药品注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2020/06/15175529929106.shtml",
    "datetime": "2020-06-15 17:55:35",
    "code": "300142"
  },
  {
    "title": "沃森生物董事徐万胜辞职 因个人原因",
    "href": "http://stock.jrj.com.cn/2020/06/05213029855407.shtml",
    "datetime": "2020-06-05 21:30:31",
    "code": "300142"
  },
  {
    "title": "沃森生物：两价HPV疫苗已进入中国上市申报阶段 将全力支持Gavi 5.0战略计划",
    "href": "http://stock.jrj.com.cn/2020/06/05184029854398.shtml",
    "datetime": "2020-06-05 18:40:01",
    "code": "300142"
  },
  {
    "title": "重磅疫苗陆续上市 沃森生物迎来业绩拐点",
    "href": "http://stock.jrj.com.cn/2020/06/05032529847784.shtml",
    "datetime": "2020-06-05 03:25:24",
    "code": "300142"
  },
  {
    "title": "沃森生物研发费率超23% 十余年研发出首个自主国产幼儿疫苗",
    "href": "http://stock.jrj.com.cn/2020/06/01080929815899.shtml",
    "datetime": "2020-06-01 08:09:33",
    "code": "300142"
  },
  {
    "title": "沃森生物聘任章建康为公司副总裁",
    "href": "http://stock.jrj.com.cn/2020/05/29233829799302.shtml",
    "datetime": "2020-05-29 23:38:41",
    "code": "300142"
  },
  {
    "title": "PK辉瑞产品、国产首个 沃森生物13价肺炎球菌疫苗全面上市",
    "href": "http://stock.jrj.com.cn/2020/05/20222429724559.shtml",
    "datetime": "2020-05-20 22:24:38",
    "code": "300142"
  },
  {
    "title": "沃森生物首个国产PCV13上市 严把安全关重塑国产疫苗信心",
    "href": "http://stock.jrj.com.cn/hotstock/2020/05/20131229720938.shtml",
    "datetime": "2020-05-20 13:12:09",
    "code": "300142"
  },
  {
    "title": "15年研发、国内首个 沃森生物13价肺炎球菌疫苗开启云南首批接种",
    "href": "http://stock.jrj.com.cn/2020/05/20115029720578.shtml",
    "datetime": "2020-05-20 11:50:20",
    "code": "300142"
  },
  {
    "title": "沃森生物：子公司泽润生物新冠疫苗研发项目获100万美元资助 有望加速临床前研究进度",
    "href": "http://stock.jrj.com.cn/2020/05/15154029681187.shtml",
    "datetime": "2020-05-15 15:40:42",
    "code": "300142"
  },
  {
    "title": "[沃森生物]上海泽润新冠疫苗研发项目获得100万美元资助",
    "href": "http://stock.jrj.com.cn/2020/05/15000029680310.shtml",
    "datetime": "2020-05-15 00:00:00",
    "code": "300142"
  },
  {
    "title": "沃森生物宣布开展新冠疫苗研究 全球首个mRNA疫苗基因序列设计算法发布 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/05/13183929662806.shtml",
    "datetime": "2020-05-13 18:39:14",
    "code": "300142"
  },
  {
    "title": "沃森生物股东工投集团减持30.74万股 套现约1153.43万元",
    "href": "http://stock.jrj.com.cn/2020/05/04151629534728.shtml",
    "datetime": "2020-05-04 15:16:49",
    "code": "300142"
  },
  {
    "title": "沃森生物工程技术总监段清堂辞职 2019年薪酬为44.06万元",
    "href": "http://stock.jrj.com.cn/2020/05/04143229533215.shtml",
    "datetime": "2020-05-04 14:32:38",
    "code": "300142"
  },
  {
    "title": "沃森生物第一季度亏损1811.77万 较上年同期由盈转亏",
    "href": "http://stock.jrj.com.cn/2020/04/26103929376576.shtml",
    "datetime": "2020-04-26 10:39:58",
    "code": "300142"
  },
  {
    "title": "沃森生物股东刘俊辉质押2100万股 用于融资",
    "href": "http://stock.jrj.com.cn/2020/04/17234029316468.shtml",
    "datetime": "2020-04-17 23:40:16",
    "code": "300142"
  }
]